Experimental pill aims to stop extra bone growth in rare disease
Disease control
Terminated
This phase 2 trial tested two doses of an oral drug called fidrisertib (IPN60130) in children and adults with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal was to see if the drug could reduce new abnormal bone growth com…
Phase: PHASE2 • Sponsor: Clementia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC